Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease

BACKGROUND: Tofacitinib has been approved for moderate-to-severe ulcerative colitis and studied in Crohn’s disease. Understanding medication adherence to oral medications in severe disease is essential. METHODS: We retrospectively reviewed adherence and real-world outcomes of inflammatory bowel dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiles, C Alex, Shah, Nisha B, Bell, Jake, Pabla, Baldeep S, Scoville, Elizabeth A, Dalal, Robin L, Beaulieu, Dawn B, Schwartz, David A, Horst, Sara N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802481/
https://www.ncbi.nlm.nih.gov/pubmed/36777280
http://dx.doi.org/10.1093/crocol/otab075
Descripción
Sumario:BACKGROUND: Tofacitinib has been approved for moderate-to-severe ulcerative colitis and studied in Crohn’s disease. Understanding medication adherence to oral medications in severe disease is essential. METHODS: We retrospectively reviewed adherence and real-world outcomes of inflammatory bowel disease patients who initiated tofacitinib at a single care center. Adherence was measured by proportion of days covered. RESULTS: Sixty-three patients were identified. All patients failed at least one prior biologic therapy. Mean proportion of days covered was 95.7% for ulcerative colitis and 93.1% for Crohn’s disease. Significant clinical and endoscopic response was seen. CONCLUSION: Adherence was high in a cohort with highly refractory disease.

Ejemplares similares